| Primary |
| Burkitt's Lymphoma |
47.1% |
| Acute Myeloid Leukaemia |
38.5% |
| Acquired Immunodeficiency Syndrome |
13.5% |
| Pneumocystis Jiroveci Infection |
1.0% |
|
| Spinal Compression Fracture |
35.3% |
| Amenorrhoea |
23.5% |
| Azoospermia |
17.6% |
| Infertility Male |
11.8% |
| Spermatozoa Progressive Motility Decreased |
5.9% |
| Thoracic Vertebral Fracture |
5.9% |
|
| Secondary |
| Acute Myeloid Leukaemia |
16.9% |
| Rhabdomyosarcoma |
13.4% |
| T-cell Lymphoma |
10.2% |
| Acute Lymphocytic Leukaemia |
9.2% |
| Burkitt's Lymphoma |
7.7% |
| Non-hodgkin's Lymphoma |
7.7% |
| Diffuse Large B-cell Lymphoma |
6.5% |
| Mantle Cell Lymphoma |
4.3% |
| Prophylaxis |
3.7% |
| T-cell Prolymphocytic Leukaemia |
3.1% |
| Acute Leukaemia |
2.4% |
| Acute Promyelocytic Leukaemia |
2.4% |
| Stem Cell Transplant |
2.4% |
| Chemotherapy |
1.8% |
| Product Used For Unknown Indication |
1.8% |
| B Precursor Type Acute Leukaemia |
1.6% |
| Hodgkin's Disease Nodular Sclerosis Stage Ii |
1.6% |
| Acquired Immunodeficiency Syndrome |
1.2% |
| Cardiac Failure |
1.2% |
| Drug Use For Unknown Indication |
1.2% |
|
| Myelitis Transverse |
12.1% |
| Pancytopenia |
12.1% |
| Pyrexia |
7.6% |
| Shock |
7.6% |
| Sepsis |
6.1% |
| Spinal Fracture |
6.1% |
| Thrombocytopenia |
6.1% |
| Cytogenetic Abnormality |
4.5% |
| Febrile Neutropenia |
4.5% |
| Neutropenic Sepsis |
4.5% |
| Purulent Discharge |
4.5% |
| Weight Decreased |
4.5% |
| Acute Graft Versus Host Disease In Skin |
3.0% |
| Diffuse Large B-cell Lymphoma |
3.0% |
| Stenotrophomonas Infection |
3.0% |
| Vomiting |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Anal Fungal Infection |
1.5% |
| Aspergillosis |
1.5% |
| Cerebellar Haemorrhage |
1.5% |
|
| Concomitant |
| Cord Blood Transplant Therapy |
24.9% |
| Prophylaxis Against Graft Versus Host Disease |
11.1% |
| Product Used For Unknown Indication |
10.7% |
| Drug Use For Unknown Indication |
7.1% |
| Acute Myeloid Leukaemia |
6.2% |
| Stem Cell Transplant |
5.8% |
| Acute Promyelocytic Leukaemia |
5.3% |
| Bone Marrow Conditioning Regimen |
5.3% |
| Prophylaxis |
4.9% |
| Pyrexia |
4.0% |
| Bone Marrow Transplant |
2.2% |
| Breast Cancer In Situ |
1.8% |
| Burkitt's Lymphoma |
1.8% |
| Pneumonia |
1.8% |
| Chronic Myeloid Leukaemia |
1.3% |
| Immunosuppressant Drug Therapy |
1.3% |
| Non-hodgkin's Lymphoma |
1.3% |
| Staphylococcal Infection |
1.3% |
| Bronchopneumonia |
0.9% |
| Depression |
0.9% |
|
| Thrombocytopenia |
9.4% |
| Venoocclusive Liver Disease |
9.4% |
| Weight Increased |
9.4% |
| Myelodysplastic Syndrome |
6.3% |
| Respiratory Failure |
6.3% |
| Serum Ferritin Increased |
6.3% |
| Spinal Shock |
6.3% |
| Thrombotic Microangiopathy |
6.3% |
| Weight Decreased |
6.3% |
| Acute Graft Versus Host Disease |
3.1% |
| B-cell Lymphoma |
3.1% |
| Choroidal Detachment |
3.1% |
| Drug Ineffective |
3.1% |
| Drug Ineffective For Unapproved Indication |
3.1% |
| Engraft Failure |
3.1% |
| Hepatitis |
3.1% |
| Liver Function Test Abnormal |
3.1% |
| Mantle Cell Lymphoma Stage Iv |
3.1% |
| Neutropenia |
3.1% |
| Pain In Extremity |
3.1% |
|
